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Management of Patients with Carotid 
Artery Stenosis
Marco Roffi1, Thomas F. Lüscher2
Zusammenfassung
Eine Stenose der A. carotis interna ist für 10–20% aller 
ischämischen Hirnschläge verantwortlich. Die Du-
plexsonographie der Karotiden bleibt die wichtigste 
diagnostische Untersuchung für Patienten mit Ver-
dacht auf Karotisstenose. Die CT-Angiographie oder 
MR-Angiographie kann zur Bestätigung der Diagnose 
und vor der Revaskularisation eingesetzt werden. Die 
invasive Angiographie ist für diagnostische Zwecke 
selten nötig. Bei symptomatischen Patienten ist eine 
Revaskularisation der Karotisarterie ab einem Steno-
segrad von 50% indiziert. Bei asymptomatischen Pa-
tienten ist die Indikation zur Revaskularisation gemäß 
den klinischen Studien ab einem Stenosegrad von 
60% gegeben, wenn das perioperative Mortalitäts- 
oder Schlaganfallrisiko auf < 3% geschätzt wird. Im 
klinischen Alltag werden aber asymptomatische Ste-
nosen meist ab einem Schweregrad von 70–80% be-
handelt, vorausgesetzt der Patient hat eine Lebenser-
wartung von mindestens 5 Jahren. Die Wahl der Re-
vaskularisationsmethode (Endarteriektomie oder 
Stenting) sollte auf dem chirurgischen Risikoprofil 
des Patienten und auf der lokalen Expertise basieren. 
Unabhängig von der Revaskularisationsmethode 
bleiben Patienten mit einer Karotisstenose aufgrund 
der hohen Prävalenz einer koronaren Herzkrankheit 
mit einem hohen kardiovaskulären Risiko behaftet. 
Eine breite Behandlungsstrategie, gestützt auf Kon-
trolle der Risikofaktoren und Änderung der Lebensge-
wohnheiten, ist in Bezug auf Lebensqualität und Le-
benserwartung wahrscheinlich besser wirksam als 
die Revaskularisation der Karotis.
Management von Patienten mit Karotisstenose
Abstract
A stenosis of the internal carotid artery may cause 
10–20% of all ischemic strokes. Duplex ultrasound is 
the diagnostic cornerstone, and CT angiography or 
MR angiography may be used to confirm the severity 
of the stenosis or prior to revascularization. Cathe-
ter-based digital subtraction angiography is rarely 
needed for diagnostic purposes. In symptomatic pa-
tients, carotid revascularization is indicated in the 
presence of a stenosis ≥ 50%. In asymptomatic pa-
tients, the indication for revascularization based on 
randomized trials is given at ≥ 60% stenosis, as long 
as the estimated perioperative death or stroke risk is 
< 3%. In clinical practice, however, asymptomatic ste-
noses are usually treated only if luminal narrowing 
exceeds 70–80% and the patient has a life expectan-
cy of at least 5 years. The choice of the revasculariza-
tion strategy (endarterectomy vs. stenting) should be 
based on the patient’s surgical risk profile and on the 
locally available expertise. Independently of the re-
vascularization option, carotid artery stenosis pa-
tients remain at risk of cardiovascular events because 
of the high prevalence of associated coronary artery 
disease. A broad disease management focusing on 
risk factor and lifestyle modification may impact 
quality and duration of life of these patients to a 
greater extent than the revascularization procedure 
itself.
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Introduction
In Western countries, stroke is the third most fre-
quent cause of death, behind cardiac disease and can-
cer, and the number 1 condition associated with per-
manent disability. A stenosis of the internal carotid 
artery may be responsible for 10–20% of all ischemic 
strokes or transient ischemic attacks (TIAs) [1]. Ath-
erosclerosis is by far the most common pathology un-
derlying carotid artery stenosis, although other disor-
ders such as carotid artery dissection, fibromuscular 
dysplasia, and Takayasu’s arteritis should be consid-
ered in the differential diagnosis. Carotid atheroscle-
rosis typically affects the origin of the internal carotid 
artery but occasionally also the distal common ca-
rotid artery. A stenosis is considered symptomatic in 
the presence of amaurosis fugax, TIA or stroke af-
fecting the corresponding territory in the preceding 
6 months. For both symptomatic and symptomatic le-
sions, the greater the severity of the stenosis, the 
greater the risk of a (recurrent) ischemic event.
In the North American Symptomatic Carotid 
Endarterectomy Trial (NASCET), the risk of recur-
rent stroke in the territory of a symptomatic carotid 
artery stenosis was 26% over 2 years (13%/year) for 
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> 70% stenoses and 18.5% over 5 years (4.4%/year) 
for 50–69% stenoses [2]. In asymptomatic patients 
with a carotid artery stenosis > 60%, the yearly risk of 
stroke is ~ 2% [3]. However, the risk may increase to 
3–4%/year in elderly patients or in the presence of 
contralateral carotid stenosis or occlusion, carotid 
plaque heterogeneity, poor collateral blood supply, 
generalized inflammatory states, and cardiac or med-
ical illnesses [2]. The main mechanism of stroke in 
patients with carotid artery stenosis is artery-to-ar-
tery embolization, although at times hypoperfusion 
may also play a role.
Diagnosis
Clinical Presentation
Asymptomatic carotid disease is usually diagnosed 
incidentally or following investigation of a neck bruit. 
However, the detection of a neck bruit is neither sen-
sitive nor specific for the presence of a clinically rel-
evant stenosis of the internal carotid artery. In pa-
tients with neurologic symptoms suggestive of brain 
ischemia, a stenosis at the level of the carotid artery 
should always be excluded. The differentiation be-
tween symptomatic and asymptomatic carotid artery 
stenosis – challenging at times – is critical because the 
two conditions may be approached differently. The 
clinical features of symptomatic carotid disease in-
clude retinal ischemia affecting the ipsilateral eye and 
hemispheric ischemia affecting the contralateral body 
half. Microembolization to the retina is perceived as 
amaurosis fugax, a transient monocular loss of vision 
that affects either the entire eye or the superior or 
inferior visual fields. Patients will often describe it as 
a shade coming down or up. Hemispheric ischemia is 
characterized by a combination of weakness, paraly-
sis, numbness or tingling, all affecting the same side 
of the body. Aphasia may be present if the dominant 
– usually the left – hemisphere is affected. Symptoms 
not suggestive of symptomatic carotid artery disease 
include diplopia, ataxia, drop attacks, vertigo, and 
loss of consciousness. To help adequately interpret 
symptoms, the involvement of a neurologist is recom-
mended.
Imaging
An imaging of the carotid arteries should be ob-
tained as soon as possible in all patients presenting 
with ischemic symptoms potentially related to a ca-
rotid source, because the estimated risk of recurrent 
ischemic event – TIA or stroke – in the 1st month is 
10–30% [4]. The most frequently used imaging mo-
dality is carotid duplex ultrasound (DUS), followed 
by computed tomography angiography (CTA), mag-
netic resonance angiography (MRA) and trans-
cranial Doppler ultrasound. The DUS velocity crite-
ria to quantify carotid artery stenosis have been de-
scribed in a recent consensus statement (Table 1) 
[5]. In high-quality laboratories, sensitivity and 
specificity for the detection of a severe stenosis of 
the internal carotid artery exceed 90%. The down-
side of this imaging modality is that the diagnostic 
accuracy is operator-dependent. CTA and MRA 
provide excellent visualization of the intra- and ex-
tracranial vessels and may be used if the DUS re-
sults are inconclusive, if a revascularization of the 
carotid artery is planned, or at the time of brain im-
aging. Catheter-based digital subtraction angiogra-
phy (DSA) remains the gold standard of carotid im-
aging. However, because of the overall excellent 
sensitivity and specificity of noninvasive imaging, 
DSA is rarely needed for diagnostic purposes. The 
major drawback of cerebral angiography is the as-
sociated stroke risk which has been estimated in re-
cent series at < 1% [6].
Table 1. Society of Radiology Consensus Panel carotid duplex ultrasound criteria for stenosis estimation (modified with per-
mission from [5]). CCA: common carotid artery; EDV: end-diastolic velocity; ICA: internal carotid artery; PSV: peak systolic ve-
locity.
Tabelle 1. Duplexultraschallkriterien zur Bestimmung des Karotisstenosegrads gemäß Society of Radiology Consensus Panel 
(mit Genehmigung modifziert nach [5]). CCA: A. carotis communis; EDV: enddiastolische Geschwindigkeit; ICA: A. carotis in-
terna; PSV: systolische Spitzengeschwindigkeit.
Degree of stenosis                    Primary parameters               Secondary parameters
 ICA PSV (cm/s) Plaque estimate (%) ICA/CCA systolic ratio ICA EDV (cm/s)
0% < 125 None < 2 < 40
< 50% < 125 < 50 < 2 < 40
50−69% 125–230 ≥ 50  2–4 40–100
≥ 70% > 230 ≥ 50 > 4 > 100
Near occlusion Variable Visible Variable Variable
Complete occlusion Undetectable  Visible, no detectable lumen 0 0
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Medical Management
A stenosis of the carotid artery should be considered 
a marker of advanced systemic atherosclerosis. In 
this patient population, long-term survival is substan-
tially decreased despite carotid revascularization [7]. 
Aggressive risk factor modification is recommended 
in all patients, irrespective of symptoms and revascu-
larization strategy, to limit progression of atheroscle-
rosis and decrease cardiovascular events [8]. Based 
on the high prevalence of coronary artery disease, a 
broad disease management may impact quality and 
duration of life to a greater extent than the revascu-
larization procedure itself [9].
Aspirin is recommended indefinitely in patients 
with carotid stenosis, irrespective of symptoms. Ac-
cording to the meta-analysis of the Antithrombotic 
Trialists’ Collaboration, patients allocated to anti-
platelet therapy had a 16% risk reduction for fatal 
stroke and a 28% risk reduction for nonfatal stroke 
compared with individuals receiving placebo [10]. In 
symptomatic patients aspirin is recommended in a 
dose ranging from 81 to 325 mg/day and there are no 
data to support higher doses, even in patients with 
recurrent TIAs on low-dose aspirin. Alternative 
treatments for symptomatic disease, none of them 
tested adequately against aspirin in this patient popu-
lation, include extended-release dipyridamole plus 
aspirin, clopidogrel, or the combination of aspirin 
and clopidogrel. Preliminary data on the combina-
tion of aspirin and clopidogrel in patients with symp-
tomatic carotid disease are promising. A small ran-
domized trial comparing dual antiplatelet therapy 
and aspirin alone in 107 patients with symptomatic 
carotid artery stenosis and Doppler-detectable mi-
croembolic signals demonstrated a significant reduc-
tion in embolic signals among patients allocated to 
dual antiplatelet therapy [11]. In a similar study, mi-
croembolic signals could be suppressed after admin-
istration of a platelet glycoprotein IIb/IIIa receptor 
inhibitor, suggesting the potential for potent platelet 
inhibition in this setting [12].
The benefit of lipid-lowering agents – and spe-
cifically statins – in patients with systemic atheroscle-
rosis is established. In addition to the lipid-lowering 
properties, statins have salutary effects on platelet 
adhesion, thrombosis, endothelial function, inflam-
mation, and plaque stability. The Heart Protection 
Study demonstrated that simvastatin produced sub-
stantial clinical benefits in a wide range of high-risk 
patients with coronary or vascular disease [13]. The 
Stroke Prevention with Aggressive Reduction of 
Cholesterol Levels (SPARCL) study showed that in 
4,731 patients with recent stroke or TIA and without 
known coronary heart disease, high-dose atorvastatin 
significantly reduced the overall incidence of stroke 
and of cardiovascular events over 5 years [14]. Al-
though studies focusing specifically on patients with 
carotid artery stenosis are lacking, statin therapy 
should be administered in all patients with this condi-
tion.
The main factor determining the reduction in the 
incidence of stroke in hypertensive patients is the de-
gree of blood pressure reduction achieved, irrespec-
tive of the medication used. Nevertheless, recent tri-
als of angiotensin-converting enzyme (ACE) inhibi-
tors and angiotensin receptor blockers (ARBs) have 
suggested that the two drug classes may convey a 
benefit in terms of stroke reduction that extends be-
yond their antihypertensive effect. The Heart Out-
comes and Prevention Evaluation (HOPE) study 
demonstrated that the ACE inhibitor ramipril signifi-
cantly reduced the rate of cardiovascular death, myo-
cardial infarction, and stroke in patients at high risk 
of cardiovascular events [15]. In the Losartan Inter-
vention For Endpoint (LIFE) trial, losartan and aten-
olol achieved similar degrees of blood pressure re-
duction, but losartan conveyed a greater reduction in 
cardiovascular events and stroke [16]. Based on the 
overall beneficial effect in high-risk vascular patients, 
ACE inhibitors or ARBs may be considered even in 
nonhypertensive patients with carotid artery disease.
Carotid Endarterectomy
Randomized Trials of Carotid End-
arterectomy Versus Medical Management
Large-scale randomized clinical trials have estab-
lished the superiority of carotid endarterectomy 
(CEA) over medical management for stroke preven-
tion in patients with high-grade internal carotid ar-
tery stenosis, particularly in the presence of symp-
toms. Among the 2,226 patients with symptomatic 
carotid artery stenosis enrolled in NASCET, the ipsi-
lateral stroke rate was reduced from 26% to 9% at 
2 years in patients with > 70% stenosis, and the corre-
sponding rate of disabling or fatal stroke was reduced 
from 13.1% to 2.5% [17, 18]. Patients with 50–69% 
luminal narrowing benefited from surgery to a lesser 
but still significant extent, with a decrease in 5-year 
ipsilateral stroke rates from 22.2% to 15.7%. Surgical 
benefit was greatest in men, in patients with hemi-
spheric rather than retinal ischemia, and in individu-
als with recent stroke rather than TIA.
The benefits of CEA for symptomatic patients 
were subsequently replicated in the European Ca-
rotid Surgery Trial (ECST) enrolling 3,024 patients 
[19]. A pooled analysis of the two trials reinforced the 
notion that the degree of stenosis above which sur-
gery was beneficial was 50%, although the benefit in 
patients with 50–69% stenosis was substantially less 
than in those with ≥ 70% stenosis. In NASCET and 
ECST, the number needed to treat in patients with 
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> 70% symptomatic stenosis – but no near occlusion 
– was 6 for ipsilateral stroke or operative death and 
14 for disabling ipsilateral stroke or operative death 
[20].
The Asymptomatic Carotid Atherosclerosis 
Study (ACAS) trial established the benefit of CEA 
over medical therapy in 1,662 asymptomatic patients 
with 60–99% internal carotid artery stenosis [21]. The 
risk profile of the population studied was similar to 
NASCET and again, surgeons and medical centers 
were highly selected. Specifically, surgeons had to 
demonstrate a 30-day death or stroke rate following 
surgery of < 3.0%. The study was terminated early 
due to improved outcomes in surgically treated pa-
tients. The 5-year stroke, including perioperative 
stroke and death, rate was reduced from 11% in the 
medically treated patients to 5.1% in those treated 
with CEA. The study had the drawback that it did not 
follow all patients for the full 5 years but rather ex-
trapolated the data.
One limitation of both NASCET and ACAS was 
limited use of evidence-based secondary preventive 
therapies such as statins or ACE inhibitors. The re-
cent Asymptomatic Carotid Surgery Trial (ACST) 
was able to confirm the benefit of CEA over medical 
therapy in 3,120 asymptomatic patients with 60–99% 
stenosis in the presence of contemporary medical 
management [19]. At 5 years, the all stroke or death 
rate was 6.4% for patients allocated to CEA and 
11.8% for those randomized to medical therapy 
(p < 0.0001). The ACST also showed that patients 
subjected to CEA were less likely to have a fatal or 
disabling stroke (3.5% in the surgical group vs. 6.1% 
in the conservative arm; p = 0.004). Finally, the study 
showed that most of the benefit was detected among 
patients aged < 75 years, while in older asymptomatic 
patient the benefit of surgery remained uncertain.
Limitations of Carotid Endarterectomy
The benefits of CEA in the randomized trials were 
conveyed by low perioperative complication rates 
(i.e., stroke and death rate of 5.8% in NASCET and 
of 2.7% in ACAS) achieved by high-volume sur-
geons on low-risk patients. Accordingly, patients 
with major medical comorbidities (e.g., uncontrolled 
hypertension or diabetes, severe renal or pulmonary 
disease, active coronary artery disease) or older 
than > 80 years of age, or those with a history of pri-
or ipsilateral endarterectomy, radical neck dissec-
tion, radiation therapy to the neck, or contralateral 
laryngeal nerve palsy, were excluded from the trials. 
In ACAS, surgeons had to demonstrate a 30-day 
death or stroke rate following surgery of < 3.0% to 
be able to enroll and during the study they were au-
dited in the presence of a high complication rate.
The results of CEA observed in the trials may 
hardly be reproduced in clinical practice. An analy-
sis involving over 110,000 patients showed that, 
while within NASCET and ACAS the perioperative 
mortality for CEA was as low as 0.6% for symptom-
atic and 0.1% for asymptomatic patients, the overall 
perioperative mortality in the hospitals participat-
ing in the trials was 1.4% [22]. In low-volume hospi-
tals, the perioperative mortality rate was 2.5%. A 
recent CEA registry from Ontario, Canada, docu-
mented a 30-day death or stroke rate of 6.0% among 
6,038 patients undergoing surgery, with an event 
rate approaching 10% in high-risk subgroups [23]. 
Although low operator and hospital volumes have 
repeatedly been associated with poor outcomes fol-
lowing CEA, in the USA the majority of surgeries 
are performed by low-volume operators. Accord-
ingly, a recent analysis including over 136,000 CEAs 
documented a mean volume per operator of 15 pro-
cedures per year, while one third of the patients 
Table 2. Pros and cons of carotid revascularization procedures (reproduced with permission from [35]).
Tabelle 2. Vor- und Nachteile von Karotisendarteriektomie und Karotisstenting (mit Genehmigung abgedruckt aus [35]).
 Endarterectomy Stenting
Pros • Widely available • Outcome less influenced by comorbidities
 • Excellent results for high-volume surgeons/hospitals in  • Local anesthesia
   low-risk patients • No neck incision/scar
  • Usually next-day discharge
Cons • Outcome influenced by comorbidities • Fewer experienced operators
 • Frequently performed in general anesthesia • Risk of the procedure may increase in patients with
 • Neck incision/scar   – severe peripheral vascular disease
 • Neck complications, cranial nerve palsies   – severely calcified, tortuous/steep aortic arch
 • Not suitable for high or low carotid lesions   – severe calcification or tortuosity of cervicocranial vessels
 • Longer hospital stay • Femoral access site complications
  •  May not be performed in case of aspirin/clopidogrel 
intolerance
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were operated on by surgeons with a mean CEA 
volume of five per year [24]. Advantages and limita-
tions of CEA are reported in Table 2.
Current Indications for Carotid 
Endarterectomy
The American Heart Association guidelines [25] 
support CEA for
•  symptomatic patients with ≥ 50% stenosis of the 
internal carotid artery,
•  asymptomatic patients with ≥ 60% stenosis of the 
internal carotid artery, as long as the life expec-
tancy is ≥ 5 years.
The benefit of CEA is established in the presence of 
a perioperative death or stroke rate of < 6% for 
symptomatic and < 3% for asymptomatic patients. 
The 2005 guidelines of the American Academy of 
Neurology recommend revascularization in eligible 
asymptomatic patients only up to the age of 75 years 
[26].
Carotid Artery Stenting
Randomized Trials of Carotid Endarterec-
tomy Versus Carotid Artery Stenting
Four major (i.e., including over 300 patients) clinical 
trials randomizing patients to CEA or carotid artery 
stenting (CAS) have been published. While the 
SAPPHIRE (Stenting and Angioplasty with Protec-
tion in Patients at HIgh Risk for Endarterectomy) 
trial [27] focused on patients – both symptomatic 
and asymptomatic – at high risk for surgery, CAVA-
TAS (CArotid and Vertebral Artery Transluminal 
Angioplasty Study [28]), SPACE (Stent-protected 
Percutaneous Angioplasty of the Carotid artery ver-
sus Endarterectomy) [29], and EVA-3S (Endarter-
ectomy Versus Angioplasty in patients with Symp-
tomatic Severe carotid Stenosis [30]) exclusively 
enrolled symptomatic patients.
CAVATAS, performed in the late 1990s, ran-
domized 504 symptomatic patients at low to moder-
ate risk for surgery to CEA or carotid angioplasty 
[28]. The incidence of death or stroke at 30 days was 
10.0% in the endovascular group and 9.9% in the 
surgical group. The outcomes among the two groups 
remained comparable at 3 years. The study has been 
criticized by the interventionalist community for the 
low stenting rate (26%) and the lack of emboli pro-
tection devices (EPDs) – unavailable at that time – 
and by the surgeons for the high event rates in the 
surgical arm.
The SAPPHIRE study is the only randomized 
trial comparing CEA and CAS performed with the 
systematic use of EPDs [27]. The trial included 
symptomatic and asymptomatic patients at high risk 
for surgery and was designed to prove the noninferi-
ority of the endovascular approach. The study was 
terminated prematurely because of slow enrollment 
due to competing CAS registries. Among the 334 
patients randomized (29% of them being symptom-
atic), major adverse events at 1 year occurred in 
12.2% in the CAS group and in 20.1% in the CEA 
group (p = 0.053). In the actual treatment analysis 
the observed difference reached statistical signifi-
cance (p = 0.048). The need for repeat carotid revas-
cularization at 1 year was lower in the CAS group 
(0.6% vs. 4.3%; p = 0.04). No cranial nerve injury 
was observed in the CAS group while this compli-
cation occurred in 5.3% of the CEA patients 
(p < 0.01). For the first time nonfatal ischemic car-
diac events were included in the outcome analysis of 
a carotid revascularization trial. Patients who un-
derwent CAS had significantly fewer myocardial 
infarctions at 30 days compared with those who 
were randomized to CEA (1.9% vs. 6.6%; p = 0.04). 
The mean length of hospital stay was 1.8 days in the 
CAS group and 2.8 days in the CEA group (p = 
0.002). The durability of CAS was documented by a 
comparable cumulative percentage of major (1.3% 
for CAS vs. 3.3% for CEA) and minor (6.1% for 
CAS vs. 3.0% for CEA) ipsilateral strokes at 3 years 
as well as by a low rate of repeat revascularization 
during the same period of time (3.0% for CAS vs. 
7.1% for CEA) [31].
The SPACE study sought to prove the noninfe-
riority of CAS compared with CEA among symp-
tomatic patients. The use of EPDs in the CAS arm 
was left at the discretion of the treating physician. 
Although the required sample size based on interim 
analysis was > 2,400 patients, the trial had to be ter-
minated following the inclusion of 1,200 patients be-
cause of slow enrollment and lack of funding. The 
incidence of ipsilateral stroke or death at 30 days 
was the primary endpoint of the study and did not 
differ between the groups, occurring in 6.8% of cas-
es in the endovascular group and in 6.3% of patients 
in the surgical arm [29].
EVA-3S was a randomized noninferiority trial 
comparing CAS with CEA in patients with a ≥ 60% 
symptomatic carotid artery stenosis. The primary 
endpoint was the cumulative incidence of any stroke 
or death within 30 days after treatment [30]. The 
trial was stopped prematurely after the inclusion of 
527 patients because of significantly increased event 
rates in the CAS arm (death or stroke 9.6% in the 
CAS arm and 3.9% in the CEA arm; p = 0.01). At 
6 months, the incidence of any stroke or death was 
11.7% in the CAS group and 6.1% in the CEA group 
(p = 0.02). The study has been heavily criticized for 
the inexperience of the interventionalists (a mini-
mum of twelve CAS procedures was required). In a 
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later correspondence, the investigators confirmed 
that 39% of patients were treated by physicians in 
training [32].
In summary, in patients at high surgical risk the 
SAPPHIRE study has demonstrated that CAS with 
adjunctive EPD is equal if not superior to surgery up 
to 1 year and that the results remain comparable at 
3 years. The benefit of revascularization over opti-
mal medical management in asymptomatic patients 
at high risk for endarterectomy is unknown because 
this question has never been addressed prospective-
ly and the impact of asymptomatic carotid artery 
disease on the natural history of these patients is un-
known. On a broader perspective, a meta-analysis of 
the four trials enrolling together over 2,500 patients 
– mostly symptomatic – was not able to detect the 
superiority of one revascularization strategy over 
the other (Figure 1).
Strengths and Limitations of Carotid Artery 
Stenting
The main advantage of CAS over CEA is that the 
endovascular approach is less invasive, performed 
in local anesthesia, and little influenced by comor-
bidities of the patient (Table 2). In addition, CAS 
may treat lesions that are not accessible to surgery 
(i.e., high in the internal carotid or low in the com-
mon carotid artery). Poor outcomes with CAS are 
usually related to challenging anatomies – such as a 
steep aortic arch or severe tortuosity of the common 
carotid arteries – as well as to poor femoral access. 
Although the procedure is feasible using a brachial 
or radial approach, the risk of complications in-
creases in this setting. In the planning phase of a 
CAS, it is useful to obtain a CTA or MRA of supra-
aortic vessels including the aortic arch to estimate 
the procedural risk. As a general rule, if unexpected 
difficulties are encountered during engagement of 
the common carotid artery because of challenging 
anatomy, surgery should be reconsidered.
The inability to place an EPD should also be 
considered a relative contraindication to CAS. How-
ever, this is rarely the case because alternative ap-
proaches to filter-based EPDs – i.e., proximal occlu-
sive devices – are available. Additional contraindi-
cations to CAS include a severe circumferential 
calcification at the level of the carotid lesion, which 
may limit stent expansion. In addition, for patients 
with severe renal insufficiency but not on dialysis or 
those with documented severe allergic reactions to 
angiographic contrast, CAS may not be the best op-
tion. Finally, for proven intolerance to aspirin or 
clopidogrel surgery should be preferred. In conclu-
sion, proper patient selection in the planning of CAS 
is as critical as adequate training. Both an improp-
erly performed procedure and an adequately per-
formed intervention on an inappropriate patient 
may result in a stroke, the very condition that CAS 
aims to prevent.
Management Algorithm
A crucial point when considering the best revascu-
larization option for an individual patient is that 
high-risk conditions for CEA and CAS differ. Ac-
cordingly, while the outcomes of CEA are mainly 
influenced by the coexisting diseases, poor outcomes 
following CAS are usually related to challenging 
anatomies as well as to poor femoral access. A man-
agement algorithm for patients with suspected ste-
nosis of the internal carotid artery is described in 
Figure 2. First of all, the degree of stenosis must be 
adequately assessed. For that purpose, it may be of 
advantage to have a second imaging modality in ad-
dition to DUS. Although randomized trials have 
documented the benefits of (surgical) revasculariza-
tion in asymptomatic patients with carotid stenosis 
≥ 60%, in clinical practice asymptomatic lesions are 
often treated only if the degree of stenosis exceeds 
70–80% and if the patient’s life expectancy is at least 
5 years. These considerations seem appropriate 
since the perioperative event rates commonly en-
CAVATAS
0.1 1.0 10
CAS better CEA better
SAPPHIRE
SPACE
EVA - 3S
Total
30-day death or stroke
Figure 1. Meta-analysis of the four published randomized studies enrolling > 300 
patients allocating patients to carotid artery stenting (CAS) or carotid endarterec-
tomy (CEA; reproduced with permission from [36]).
Abbildung 1. Metaanalyse der vier publizierten Studien, die > 300 Patienten zu 
Endarteriektomie (CEA) oder Karotisstenting (CAS) randomisiert haben (mit Ge-
nehmigung abgedruckt aus [36]).
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countered may be higher than those observed in the 
randomized trials [22, 23]. Once the indication for 
revascularization is established, the surgical risk of 
the patient should be assessed. If the patient is at 
high risk for surgery, CAS with the use of EPDs may 
be the first choice, as long as the expertise is avail-
able and the patient does not have contraindications 
to CAS. Specifically, CAS is preferred for restenosis 
following CEA, in the presence of contralateral ca-
rotid occlusion, and in patients awaiting open heart 
surgery [33, 34]. CAS should also been considered 
for patients who recently underwent coronary 
drug-eluting stent implantation as any surgical pro-
cedure – even if performed under aspirin and clopi-
dogrel – may be associated with an increased risk of 
stent thrombosis. In patients at low risk for surgery, 
CEA may be the preferred strategy. Alternatively, 
those patients may be treated with CAS and EPD 
within study protocols or in high-volume centers.
Conclusion
A stenosis of the internal carotid artery may cause 
10–20% of all ischemic strokes. DUS is the diagnos-
tic cornerstone, and CTA or MRA may be used to 
confirm the severity of the stenosis or prior to revas-
cularization. Catheter-based DSA is rarely needed 
for diagnostic purposes. In symptomatic patients, 
carotid revascularization is indicated in the presence 
of a stenosis ≥ 50%. In asymptomatic patients, the 
indication for revascularization based on random-
ized trials is given at ≥ 60% stenosis, as long as the 
estimated perioperative death or stroke risk is < 3%. 
In clinical practice, however, asymptomatic stenoses 
are usually treated only if luminal narrowing exceeds 
70–80% and the patient has a life expectancy of at 
least 5 years. The choice of the revascularization 
strategy (CEA vs. CAS) should be based on the pa-
tient’s surgical risk profile and on the locally available 
expertise. Independently of the revascularization op-
tion, carotid artery stenosis patients remain at risk of 
cardiovascular events because of the high prevalence 
of associated coronary artery disease. A broad dis-
ease management focusing on risk factor and lifestyle 
modification may impact quality and duration of life 
of these patients to a greater extent than the revascu-
larization procedure itself.
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Low risk
Assessment of the risk for CEA
CEA; alternatively CAS + EPD
within a protocol or in high-volume centers
High risk
CAS + EPD or CEA based on local expertise
CAS preferred for
• Recurrent stenosis post surgery
• Contralateral stenosis/occlusion
• Prior to open heart surgery
• Following recent implantation of a coronary DES
Yes
Suspected stenosis of the
internal carotid artery
Duplex ultrasound
Symptomatic stenosis ≥ 50%
or
asymptomatic stenosis ≥ 70−80%
and life expectancy ≥ 5 years
No MRA or
CTA (or
contrast angiography)
Duplex 
inconclusive
Conservative management
For all patients
Antiplatelet therapy
Blood pressure < 130/80 mmHg
LDL cholesterol < 100 mg/dl
Figure 2. Suggested 
algorithm for the 
management of pa-
tients with suspected 
internal carotid artery 
stenosis (modified 
with permission from 
[35]). CAS: carotid ar-
tery stenting; CEA: ca-
rotid endarterectomy; 
DES: drug-eluting 
stent; EPD: emboli 
protection device.
Abbildung 2. Empfoh-
lener Algorithmus für 
die Abklärung und Be-
handlung von Patien-
ten mit Stenose der A. 
carotis interna (mit 
Genehmigung abge-
druckt aus [35]). CAS: 
Karotisstenting; CEA: 
Karotisendarteriekto-
mie; DES: Medika-
mente freisetzender 
Stent; EPD: Embolie-
protektionssystem.
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